Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium‐based contrast agents

Publisher： John Wiley & Sons Inc

E-ISSN： 1522-2586|41|5|1259-1267

ISSN： 1053-1807

Source： JOURNAL OF MAGNETIC RESONANCE IMAGING, Vol.41, Iss.5, 2015-05, pp. : 1259-1267

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Application of Gadolinium-Based Contrast Agents and Prevalence of Nephrogenic Systemic Fibrosis in a Cohort of End-Stage Renal Disease Patients on Hemodialysis

By  

Nephron Clin Pract, Vol. 121, Iss. 1-2, 2012-11 ,pp. : c91-c94

Karger

Access to resources Recommend Favorite

Gadolinium-Contrast Toxicity in Patients with Kidney Disease: Nephrotoxicity and Nephrogenic Systemic Fibrosis

By  

Current Drug Safety, Vol. 3, Iss. 1, 2008-01 ,pp. : 67-75

Bentham Science Publishers

Access to resources Recommend Favorite

Gadolinium-based Imaging Contrast Agents

By  

Current Medical Imaging Reviews, Vol. 10, Iss. 2, 2014-05 ,pp. : 140-150

Bentham Science Publishers

Access to resources Recommend Favorite

Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis?

By Grobner Thomas   Mayer Gert J.   Rosenkranz Alexander R.  

Wiener klinische Wochenschrift, Vol. 119, Iss. 9-10, 2007-06 ,pp. : 271-275

Springer Publishing Company

Access to resources Recommend Favorite

Nephrogenic systemic fibrosis in a gadolinium‐naïve patient: Successful treatment with oral sirolimus

By  

AUSTRALASIAN JOURNAL OF DERMATOLOGY, Vol. 56, Iss. 3, 2015-08 ,pp. : e59-e62

John Wiley & Sons Inc

Access to resources Recommend Favorite